title: Cytotoxic efficacy of photodynamic therapy in osteosarcoma cells in vitro.
abstract: In recent years, there has been the difficulty in finding more effective therapies against cancer with less systemic side effects. Therefore Photodynamic Therapy is a novel approach for a more tumor selective treatment. Photodynamic Therapy (PDT) that makes use of a nontoxic photosensitizer (PS), which, upon activation with light of a specific wavelength in the presence of oxygen, generates oxygen radicals that elicit a cytotoxic response(1). Despite its approval almost twenty years ago by the FDA, PDT is nowadays only used to treat a limited number of cancer types (skin, bladder) and nononcological diseases (psoriasis, actinic keratosis)(2). The major advantage of the use of PDT is the ability to perform a local treatment, which prevents systemic side effects. Moreover, it allows the treatment of tumors at delicate sites (e.g. around nerves or blood vessels). Here, an intraoperative application of PDT is considered in osteosarcoma (OS), a tumor of the bone, to target primary tumor satellites left behind in tumor surrounding tissue after surgical tumor resection. The treatment aims at decreasing the number of recurrences and at reducing the risk for (postoperative) metastasis. In the present study, we present in vitro PDT procedures to establish the optimal PDT settings for effective treatment of widely used OS cell lines that are used to reproduce the human disease in well established intratibial OS mouse models. The uptake of the PS mTHPC was examined with a spectrophotometer and phototoxicity was provoked with laser light excitation of mTHPC at 652 nm to induce cell death assessed with a WST-1 assay and by the counting of surviving cells. The established techniques enable us to define the optimal PDT settings for future studies in animal models. They are an easy and quick tool for the evaluation of the efficacy of PDT in vitro before an application in vivo.
authors.affiliation: Laboratory for Orthopedic Research, Balgrist University Hospital, Zurich, Switzerland; dmeier@research.balgrist.ch.
authors.forename: Daniela
authors.initials: D
authors.lastname: Meier
authors.affiliation: Laboratory for Orthopedic Research, Balgrist University Hospital, Zurich, Switzerland; ccampanile@research.balgrist.ch.
authors.forename: Carmen
authors.initials: C
authors.lastname: Campanile
authors.affiliation: Laboratory for Orthopedic Research, Balgrist University Hospital, Zurich, Switzerland; sbotter@research.balgrist.ch.
authors.forename: Sander M
authors.initials: SM
authors.lastname: Botter
authors.affiliation: Laboratory for Orthopedic Research, Balgrist University Hospital, Zurich, Switzerland; wborn@research.balgrist.ch.
authors.forename: Walter
authors.initials: W
authors.lastname: Born
authors.affiliation: Laboratory for Orthopedic Research, Balgrist University Hospital, Zurich, Switzerland; research@balgrist.ch.
authors.forename: Bruno
authors.initials: B
authors.lastname: Fuchs
mesh_terms: D000818:Animals; D001859:Bone Neoplasms / Q000188:drug therapy*; D045744:Cell Line, Tumor; D006801:Humans; D008652:Mesoporphyrins / Q000493:pharmacokinetics / Q000494:pharmacology; D051379:Mice; D016513:Mice, SCID; D012516:Osteosarcoma / Q000188:drug therapy*; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000493:pharmacokinetics / Q000494:pharmacology
chemical_list: D008652:Mesoporphyrins; D017319:Photosensitizing Agents; C072269:temoporfin